Description: Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic.
Home Page: equilliumbio.com
EQ Technical Analysis
2223 Avenida De La Playa
La Jolla,
CA
92037
United States
Phone:
858 412 5302
Officers
| Name | Title |
|---|---|
| Mr. Daniel Mark Bradbury | Exec. Chairman |
| Mr. Bruce D. Steel C.F.A. | Co-Founder, CEO & Director |
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer & Director |
| Mr. Jason A. Keyes | Chief Financial Officer |
| Ms. Christine Zedelmayer M.B.A., P.M.P. | Sr. VP & COO |
| Mr. Michael Moore | VP of Investor Relations & Corp. Communications |
| Matthew Ritter Ph.D. | Sr. VP of Corp. Devel. |
| Dr. Krishna R. Polu M.D. | Consultant |
| Mr. Joel M. Rothman | Chief Devel. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4883 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2018-10-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 45 |